---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42681760.md"
description: "$Agenus(AGEN.US) fell back -17% today, which is actually profit-taking after Monday's doubling surge—it announced three-year Phase 1b data for the botensilimab plus balstilimab combination in refractory colorectal cancer, with a median overall survival of 21.2 months, causing it to surge directly by 100% on Monday, and HC Wainwright maintained a Buy rating and raised the target price to $30.The current dilemma is: after the data-driven doubling, it has pulled back significantly. Is this normal digestion of profit-taking, presenting a buying opportunity on dips, or is it a one-time data catalyst that's now exhausted with no follow-up? It looks more like the former—the real next catalyst will be waiting for the registration pathway and subsequent clinical updates. Pulling back to a level with no new news is actually an observation window, but with such volatility in small-cap Biotech, don't go too heavy on the position."
datetime: "2026-07-15T10:26:35.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42681760.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42681760.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42681760.md)
author: "[本职喵星人](https://longbridge.com/en/profiles/27713076.md)"
---

# $Agenus(AGEN.US) fell back -17% today, which is ac…


### Related Stocks

- [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md)
- [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md)